18 and older, any sex, with Degeneration Articular Cartilage Knee. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
IKDC ScorePrimary· 12 months
Subjects underwent a self-assessment of knee function using the IKDC (International Knee Documentation Committee Assessment)subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms.
The IKDC assessment was performed before IP administration and at Months 12 after IP administration in an exploratory fashion. The IKDC
Group
Value
95% CI
Dose A Cohort
32.0
± 27.7
Dose B Cohort
25.5
± 18.9
VASSecondary· 24 months
Subjects underwent a self-assessment of joint pain using the 100-mm VAS (Visual Analogue Scale) before and at Months 12 and 24 after IP (investigational product) administration. Higher values represent worse joint pain. Use of NSAIDs and any other analgesics had to be discontinued for 48 hours and 24 hours, respectively, prior to the 100 mm VAS evaluation. The outcome was presented with the post-operative change amount at Months 12 and 24 from the baseline.
100-mm VAS scores range from 0 to 100. Higher values represent worse joint pain.
12 MONTHS
Group
Value
95% CI
Dose A Cohort
-23.8
± 22.9
Dose B Cohort
-12.5
± 31.5
24 MONTHS
Group
Value
95% CI
Dose A Cohort
-31.7
± 18.0
Dose B Cohort
-11.3
± 30.2
Lysholm ScoreSecondary· 24 months
The Lysholm knee scoring scale is a self-assessment that rates the severity of common complaints related to knee problems, such as pain, swelling, abnormal sensations, and ability to squat or climb stairs. The possible score ranges from 0 to 100, where 100 = no symptoms or disability. Scores are categorized as excellent (95 to 100), good (84 to 94), fair (65 to 83), and poor (≤64). Subjects underwent a self-assessment of knee function using the Lysholm score before IP administration and at Months 12 and 24 after IP administration. The outcome was presented with the post-operative change amount
12 MONTHS
Group
Value
95% CI
Dose A Cohort
26.7
± 20.5
Dose B Cohort
22.5
± 18.3
24 MONTHS
Group
Value
95% CI
Dose A Cohort
32.0
± 20.9
Dose B Cohort
10.2
± 13.0
KOOS ScoreSecondary· 24 months
The Knee Injury and Osteoarthritis Outcome score (KOOS) knee survey is a self assessment of knee function and knee-related quality of life (QOL). Subjects responded to each question regarding knee-related symptoms, swelling, pain, impaired function, or changes in QOL with 1 of 5 possible answers that range from "never/not at all" to "always/extremely." The possible score for each parameter ranges from 0 to 100, where 0=extreme problems and 100=no problems. Subjects completed the KOOS knee survey before IP (investigational product) administration and at Month 24 after IP administration. The out
ADL (24 MONTHS)
Group
Value
95% CI
Dose A Cohort
28.2
± 25.7
Dose B Cohort
12.3
± 19.2
PAIN (24 MONTHS)
Group
Value
95% CI
Dose A Cohort
23.6
± 24.3
Dose B Cohort
15.8
± 13.1
QOL (24 MONTHS)
Group
Value
95% CI
Dose A Cohort
50.0
± 36.4
Dose B Cohort
19.8
± 24.2
SPORTS (24 MONTHS)
Group
Value
95% CI
Dose A Cohort
39.2
± 37.2
Dose B Cohort
36.7
± 31.9
SYMPTOM (24 MONTHS)
Group
Value
95% CI
Dose A Cohort
24.4
± 19.9
Dose B Cohort
8.3
± 12.3
IKDC ScoreSecondary· 24 months
Subjects underwent a self-assessment of knee function using the IKDC subjective knee evaluation before and after the administration of the IP. The assessment is designed to detect improvement or deterioration in symptoms, function, and sports activities due to knee impairment. The possible score ranges from 0 to 100, where 100 = no limitation with daily or sporting activities and the absence of symptoms. The IKDC assessment was performed before IP administration and at Month 24 after IP administration in an exploratory fashion. The outcome was presented with the post-operative change amount at
Group
Value
95% CI
Dose A Cohort
41.2
± 25.8
Dose B Cohort
27.5
± 20.9
Adverse events — posted to ClinicalTrials.gov
Time frame: 24 months.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to determine whether CARTISTEM, a cell therapeutic product, is safe and effective in the treatment of articular cartilage defects of the knee as a result of ageing, trauma, or degenerative diseases.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medipost, Inc.
Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01733186.